Mayo Clinic’s Immunome IMNM Stock Holding History

Mayo Clinic’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-108,480	Closed	-$1.16M	–	7
2023 Q4	$1.16M	Buy	+108,480	New	+$902K	7.17%	3

Other funds holding IMNM

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Mayo Clinic's IMNM Position: Q1 2024 in Review

Mayo Clinic sold out of Immunome (IMNM) in Q1 2024, closing a stake of 108,480 shares — an estimated $1.16M sold.

Mayo Clinic first reported a position in IMNM in Q4 2023 and held it in 1 quarter. The position peaked at $1.16M in Q4 2023. 104 funds tracked by Wall St. Rank hold IMNM as of Q1 2024.

Mayo Clinic reported no remaining Immunome position as of Q1 2024 after selling out during the quarter.
Mayo Clinic sold 108,480 Immunome shares in Q1 2024, an estimated $1.16M.
Mayo Clinic first reported a position in Immunome in Q4 2023 and held it in 1 quarter.
Mayo Clinic's Immunome position peaked at $1.16M in Q4 2023.
104 funds tracked by Wall St. Rank held Immunome as of Q1 2024.

Based on Mayo Clinic's 13F filing for Q1 2024, filed 13 May 2024.